Cargando…

Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice

INTRODUCTION: Rituximab (RTX) and recombinant human myelin basic protein (rhMBP) were proven to be effective in ameliorating the symptoms of multiple sclerosis (MS). In this study, a nanoformulation containing rhMBP with RTX on its surface (Nano-rhMBP-RTX) was prepared and investigated in comparison...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Muhammed A, Eissa, Noha M, Ahmed, Mohammed A, ElMeshad, Aliaa N, Laible, Götz, Attia, Ahmed S, Al-Ghobashy, Medhat A, Abdelsalam, Rania M, Al-Shorbagy, Muhammad Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464642/
https://www.ncbi.nlm.nih.gov/pubmed/36105617
http://dx.doi.org/10.2147/IJN.S359114
_version_ 1784787628604784640
author Saad, Muhammed A
Eissa, Noha M
Ahmed, Mohammed A
ElMeshad, Aliaa N
Laible, Götz
Attia, Ahmed S
Al-Ghobashy, Medhat A
Abdelsalam, Rania M
Al-Shorbagy, Muhammad Y
author_facet Saad, Muhammed A
Eissa, Noha M
Ahmed, Mohammed A
ElMeshad, Aliaa N
Laible, Götz
Attia, Ahmed S
Al-Ghobashy, Medhat A
Abdelsalam, Rania M
Al-Shorbagy, Muhammad Y
author_sort Saad, Muhammed A
collection PubMed
description INTRODUCTION: Rituximab (RTX) and recombinant human myelin basic protein (rhMBP) were proven to be effective in ameliorating the symptoms of multiple sclerosis (MS). In this study, a nanoformulation containing rhMBP with RTX on its surface (Nano-rhMBP-RTX) was prepared and investigated in comparison with other treatment groups to determine its potential neuro-protective effects on C57BL/6 mice after inducing experimental autoimmune encephalomyelitis (EAE). METHODS: EAE was induced in the corresponding mice by injecting 100 μL of an emulsion containing complete Freund’s adjuvant (CFA) and myelin oligodendrocyte glycoprotein (MOG). The subjects were weighed, scored and subjected to behavioural tests. After reaching a clinical score of 3, various treatments were given to corresponding EAE-induced and non-induced groups including rhMBP, RTX, empty nanoparticle prepared by poly (lactide-co-glycolide) (PLGA) or the prepared nanoformulation (Nano-rhMBP-RTX). At the end of the study, biochemical parameters were also determined as interferon-γ (IFN-γ), myeloperoxidase (MPO), interleukin-10 (IL-10), interleukin-4 (IL-4), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-kB), brain derived neurotrophic factor (BDNF), 2’, 3’ cyclic nucleotide 3’ phosphodiesterase (CNP) and transforming growth factor beta (TGF-β) along with some histopathological analyses. RESULTS: The results of the Nano-rhMBP-RTX group showed promising outcomes in terms of reducing the clinical scores, improving the behavioural responses associated with improved histopathological findings. Elevation in the levels of IL-4, CNP and TGF-β was also noticed along with marked decline in the levels of NF-kB and TNF-α. CONCLUSION: Nano-rhMBP-RTX treated group ameliorated the adverse effects induced in the EAE model. The effectiveness of this formulation was demonstrated by the normalization of EAE-induced behavioral changes and aberrant levels of specific biochemical markers as well as reduced damage of hippocampal tissues and retaining higher levels of myelination.
format Online
Article
Text
id pubmed-9464642
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94646422022-09-13 Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice Saad, Muhammed A Eissa, Noha M Ahmed, Mohammed A ElMeshad, Aliaa N Laible, Götz Attia, Ahmed S Al-Ghobashy, Medhat A Abdelsalam, Rania M Al-Shorbagy, Muhammad Y Int J Nanomedicine Original Research INTRODUCTION: Rituximab (RTX) and recombinant human myelin basic protein (rhMBP) were proven to be effective in ameliorating the symptoms of multiple sclerosis (MS). In this study, a nanoformulation containing rhMBP with RTX on its surface (Nano-rhMBP-RTX) was prepared and investigated in comparison with other treatment groups to determine its potential neuro-protective effects on C57BL/6 mice after inducing experimental autoimmune encephalomyelitis (EAE). METHODS: EAE was induced in the corresponding mice by injecting 100 μL of an emulsion containing complete Freund’s adjuvant (CFA) and myelin oligodendrocyte glycoprotein (MOG). The subjects were weighed, scored and subjected to behavioural tests. After reaching a clinical score of 3, various treatments were given to corresponding EAE-induced and non-induced groups including rhMBP, RTX, empty nanoparticle prepared by poly (lactide-co-glycolide) (PLGA) or the prepared nanoformulation (Nano-rhMBP-RTX). At the end of the study, biochemical parameters were also determined as interferon-γ (IFN-γ), myeloperoxidase (MPO), interleukin-10 (IL-10), interleukin-4 (IL-4), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-kB), brain derived neurotrophic factor (BDNF), 2’, 3’ cyclic nucleotide 3’ phosphodiesterase (CNP) and transforming growth factor beta (TGF-β) along with some histopathological analyses. RESULTS: The results of the Nano-rhMBP-RTX group showed promising outcomes in terms of reducing the clinical scores, improving the behavioural responses associated with improved histopathological findings. Elevation in the levels of IL-4, CNP and TGF-β was also noticed along with marked decline in the levels of NF-kB and TNF-α. CONCLUSION: Nano-rhMBP-RTX treated group ameliorated the adverse effects induced in the EAE model. The effectiveness of this formulation was demonstrated by the normalization of EAE-induced behavioral changes and aberrant levels of specific biochemical markers as well as reduced damage of hippocampal tissues and retaining higher levels of myelination. Dove 2022-09-07 /pmc/articles/PMC9464642/ /pubmed/36105617 http://dx.doi.org/10.2147/IJN.S359114 Text en © 2022 Saad et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Saad, Muhammed A
Eissa, Noha M
Ahmed, Mohammed A
ElMeshad, Aliaa N
Laible, Götz
Attia, Ahmed S
Al-Ghobashy, Medhat A
Abdelsalam, Rania M
Al-Shorbagy, Muhammad Y
Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
title Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
title_full Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
title_fullStr Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
title_full_unstemmed Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
title_short Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
title_sort nanoformulated recombinant human myelin basic protein and rituximab modulate neuronal perturbations in experimental autoimmune encephalomyelitis in mice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464642/
https://www.ncbi.nlm.nih.gov/pubmed/36105617
http://dx.doi.org/10.2147/IJN.S359114
work_keys_str_mv AT saadmuhammeda nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT eissanoham nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT ahmedmohammeda nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT elmeshadaliaan nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT laiblegotz nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT attiaahmeds nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT alghobashymedhata nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT abdelsalamraniam nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice
AT alshorbagymuhammady nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice